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Abstract
Human endogenous retrovirus (HERV) genomes are chromosomally integrated in all cells of an individual. They are normally
transcriptionally silenced and transmitted only vertically. Enhanced expression of HERV-K accompanied by the emergence of
anti-HERV-K-directed immune responses has been observed in tumor patients and HIV-infected individuals. As HERV-K is
usually not expressed and immunological tolerance development is unlikely, it is an appropriate target for the development
of immunotherapies. We generated a recombinant vaccinia virus (MVA-HKenv) expressing the HERV-K envelope
glycoprotein (ENV), based on the modified vaccinia virus Ankara (MVA), and established an animal model to test its
vaccination efficacy. Murine renal carcinoma cells (Renca) were genetically altered to express E. coli beta-galactosidase (RLZ
cells) or the HERV-K ENV gene (RLZ-HKenv cells). Intravenous injection of RLZ-HKenv cells into syngenic BALB/c mice led to
the formation of pulmonary metastases, which were detectable by X-gal staining. A single vaccination of tumor-bearing
mice with MVA-HKenv drastically reduced the number of pulmonary RLZ-HKenv tumor nodules compared to vaccination
with wild-type MVA. Prophylactic vaccination of mice with MVA-HKenv precluded the formation of RLZ-HKenv tumor
nodules, whereas wild-type MVA-vaccinated animals succumbed to metastasis. Protection from tumor formation correlated
with enhanced HERV-K ENV-specific killing activity of splenocytes. These data demonstrate for the first time that HERV-K
ENV is a useful target for vaccine development and might offer new treatment opportunities for diverse types of cancer.
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Introduction
Human endogenous retroviruses (HERVs) are relics of evolu-
tionary ancient viral infection events into the germ line which are
now transmitted vertically. These retrovirus genomes are chro-
mosomally integrated in all the cells of an individual and their
sequences comprise about 8% of the human genome [1]. HERVs
are classified by the single letter amino acid code for the tRNA
specific for the primer-binding site used to initiate reverse
transcription. At present, 11 distantly related HERV groups with
a tRNA lysine (K) primer binding site are known (reviewed in [2]).
One of these, the HERV-K/HML-2(hom) group, is the only
known endogenous retrovirus group encoding all structural and
enzymatic proteins. For reasons of simplicity, HERV-K/HML-
2(hom) will hereafter be abridged to HERV-K.
Retroviruses have the ability to integrate their sequences into
the cellular genome which may result in cell transformation and
cancer caused by insertional mutagenesis. Therefore, endogenous
retroviruses had to be highly regulated shortly after they entered
the human species [3], [4]. Consequently, HERV-K gene
expression is generally found to be repressed and immunological
tolerance is unlikely. However, HERV-K expression occurs and
has been described in conjunction with disease. Reactivation of
HERV-K proviruses coding for all viral proteins is well established
for human teratocarcinomas [5], melanomas [6], [7] and ovarian
cancer [8], [9]. HERV-K ENV has been found to be
overexpressed in breast cancer tissues [10], [11]. The overexpres-
sion of Gag has been seen in the peripheral blood cells of leukemia
patients [12] and also in prostate cancer and ovarian cancer but
not in healthy donors [13], [14]. Furthermore, it has been
reported that HIV infection leads to increased expression of
HERVs, and T cell responses to HERV peptides have been
detected in HIV-1-infected patients [15], [16], [17], [18], [19],
[20]. Individuals who control HIV-1 viremia without highly active
antiretroviral therapy (HAART) had stronger and broader
HERV-specific T cell responses than HAART-suppressed pa-
tients, virologic noncontrollers, immunologic progressors, and
uninfected controls. An inverse correlation between anti-HERV-K
T cell responses and HIV-1 viral load has also been detected [21],
[22]. Recently, a HERV-K-specific CD8+ T cell clone could be
isolated, which eliminated cells infected with a panel of globally
diverse HIV-1, HIV-2, and SIV isolates in vitro [23]. This indicates
a potential therapeutic value of HERV-K-directed T cell
responses for HIV-infected patients on the one hand and, on the
other, suggests a lack of immune tolerance to HERVs in HIV-
infected individuals and most likely also in healthy individuals.
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the HIV patients and give first indications that a HERV-K vaccine
might be safe. Additionally, expression of HERV-K proteins was
recently assessed by immunohistochemical analysis of human
tissue. Several human tissues expressing HERV-K Gag were
identified; however, no healthy human tissue showed HERV-K
ENV expression [24]. Another study found HERV-K ENV
protein expression in villous and extravillous cytotrophoblast cells
of the human placenta [25]. Simian endogenous retrovirus K
(SERV-K) expression has been observed in several tissues of
nonhuman primates [24]. Vaccination of rhesus macaques which
carry SERV-K with SERV-K Gag or ENV induced T cell
responses without vaccine-related pathogenicity [24]. In summary,
these data support the notion that HERV-K ENV-directed
immune responses might be induced safely in humans.
There is good evidence that tumor-associated antigens (TAAs)
can be used for therapeutic vaccinations, in particular for the
treatment of minimal residual disease. Furthermore, induction of
immunological memory may prevent disease relapse. Poxviruses
are attractive vaccine vectors. They activate robust cellular MHC
class I- and II-restricted CD8+ and CD4+ T cell responses against
recombinant antigens. This, for instance, has been shown for NY-
ESO-1, a marker for a range of human malignancies [26].
Recombinant vaccinia-NY-ESO-1 and recombinant fowlpox-NY-
ESO-1 were used as vaccines in 36 patients with different tumor
types. In several patients with melanoma, the natural course of the
disease was favorably influenced by vaccination [26]. Likewise, the
attenuated modified vaccinia virus Ankara (MVA) has been
extensively used as vector for the delivery of TAAs in preclinical
studies and clinical trials for the treatment and/or prevention of
different cancer types [27]. Due to the excellent safety profile of
MVA, also in immunosuppressed patients, along with its retained
high immunogenicity, it is widely considered as the vaccinia virus
strain of choice for clinical investigation.
Here we generated a recombinant MVA expressing the HERV-
K envelope glycoprotein, and tested its ability to act as a cancer
vaccine in a syngenic mouse tumor model using HERV-K ENV-
expressing murine renal carcinoma cells (Renca).
Materials and Methods
Ethics Statement
This study was carried out in strict accordance with the
recommendations in the German Animal Licence regulations
(Tierschutzgesetz). The protocol was approved by the Committee
on the Ethics of Animal Experiments of the Regional Council
Darmstadt (Permit Number: V54 19c 20/15 F107/93). All efforts
were made to minimize suffering.
Generation of Recombinant MVA
The HERV-K envelope gene sequences were excised from the
plasmid pHKges, containing the HERV-K genome controlled by
a CMV promoter, by BciVI/SphI digestion, treated with T4 DNA
polymerase to generate blunt ends, and cloned into the blunted
AscI site of MVA expression plasmid pVIdHR-P7.5 to generate
the MVA vector plasmid pVI-HKEnv. Upon transfection into
MVA-infected cells, the plasmid directs insertion of foreign genes
into the site of deletion VI within the MVA genome and allows
transcription of the HERV-K ENV gene under control of the
vaccinia virus-specific promoter P7.5. The recombinant virus
MVA-HKenv was generated in BHK-21 cells by transfection with
1 mg of plasmid DNA, infection at an MOI of 0.05 with MVA-
IInew isolate, and plaque selection on RK13 cells [28], [29].
BHK-21 and RK13 cells were obtained from American Type
Culture Collection (ATCC) (ATCC-CCL-10 and ATCC-CCL-37
respectively). The recombinant MVA genomes were analyzed by
PCR to verify HERV-K ENV gene insertion and genetic stability.
Multiple-step growth analysis in chicken embryo fibroblasts (CEFs)
demonstrated that the replication capacity of MVA-HKenv was
slightly less efficient compared to wild-type MVA. MVA
preparations for immunizations were generated by amplification
in CEFs. MVA and MVA-HKenv were purified by ultracentri-
fugation through sucrose, reconstituted in 1 mmol/L Tris/HCl
(pH 9.0) and quality controlled once more by PCR and for
microbial contaminations.
Western Blot
Western blot was performed with a BIO-Rad semi-dry blotter.
Proteins separated by SDS-PAGE were blotted onto PVDF
membranes with 50 mM sodium borate pH 9.0, 20% methanol
and 0.1% SDS at 100 mA per membrane for 75 min. Afterwards,
membranes were blocked with Roti-Block
TM and proteins were
detected with a-HERV-K ENV monoclonal antibody (HERM-
1811-5; Austral biological, Binzwangen, Germany) and the ECL
detection system (Amersham, Freiburg).
Immunofluorescence Staining of Cells
Cells were fixed with 2% paraformaldehyd and HERV-K ENV
was detected after successive incubations with an anti-HERV-K
ENV antibody (HERM-1811-5) and a TRITC-coupled goat anti-
mouse IgG antibody (DAKO, Hamburg, Germany). Additionally
cells were stained with DAPI. Cells were examined with a
4006magnification.
Cell Culture
HEK 293 T (ATCC: CRL11268), BHK21 (ATCC: CCL-10)
and RK-13 (ATCC: CCL-37) cells were cultured in complete
Dulbecco’s modified Eagle’s medium (DMEM) containing 10%
fetal bovine serum and L-glutamine (2 mM). Renca-lacZ (RLZ)
cells were cultured in RPMI medium complemented with 10%
fetal bovine serum, L-glutamine (2 mM) and 250 mg/ml Zeocin
(Invitrogen, Darmstadt, Germany). For the generation of the
RLZ-HKenv cell line, MLV-based retroviral vectors were
produced encoding a codon-optimized HERV-K ENV gene
(provided by R. Lo ¨wer) via the pBabe-puro vector. For selection of
transduced cells, 1 mg/ml puromycin was added to the RLZ-
HKenv medium. The cell lines were propagated applying
standard techniques.
Detection of MVA-specific T Cells
PE-labeled MHC class I pentamers detecting B8R-specific T
cells (TSYKFESV-K
b) in C57BL/6 mice were purchased from
ProImmune and used as recommended by the manufacturer using
only half of the suggested amount of pentamer.
Animal Experiments
Female specific pathogen-free 6–8-week-old BALB/c or
C57BL/6 mice were purchased from Harland. For tumor
transplantations, RLZ-HKenv cells were grown to 60–80%
confluence and detached from the culture dish via trypsin
digestion. Cells were washed three times with PBS and
resuspended in PBS at a density of 1610
5 cells/100 ml for
therapeutic vaccination experiments, and 5610
5 cells/100 ml for
prophylactic vaccination experiments. Indicated cell numbers
were injected in the tail vein of mice using standard techniques.
Mice were immunized with the indicated amounts of recombinant
MVA intra-muscularly into the quadriceps muscles of the hind
HERV-K Env Tumor Vaccination
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indicated time points, and the lungs were prepared and incubated
in fixing solution (0.2% glutaraldehyde, 2% formaldehyde in PBS)
overnight at 4uC. For X-Gal staining, lungs were incubated in
staining solution (5 mM potassium ferrocyanide, 1 mM MgCl2,
1 mg/ml X-Gal in PBS) for 24 h. Stained lungs were stored in
PBS containing 4% formaldehyde.
T Cell Assay
The specific cytolytic activity of restimulated spleen cells was
measured by a flow cytometry-based assay. RLZ-HKenv cells
were stained with the cell membrane-labeling dye PKH67 (Sigma-
Aldrich, Munich, Germany), following the manufactures’ instruc-
tions, and then seeded at a density of 1.25610
5 cells per 24 well
one day before the assay. Spleens of vaccinated mice were excised
and suspended by passing through a 70 mm filter. For the
restimulation, 5610
6 spleen cells were cocultured with c-irradiated
(100 Gray) RLZ-HKenv cells in the presence of 200 U/ml
murine-IFN-c and 10 U/ml murine IL-2 in 6 wells. After 48 h,
splenic cells were seeded on freshly plated c-irradiated RLZ-
HKenv cells. Incubation lasted 4 days in total. The restimulated
spleen cells were counted and cocultivated with labeled target cells
(RLZ-HKenv or RLZ) at the indicated ratios for 6 h. Subse-
quently, cells were harvested with trypsin, washed, stained with PI
and analyzed directly by flow cytometry, using an LSRII
instrument (BD Biosciences, Heidelberg, Germany) and the FACS
Diva Software. Target cells were identified by PKH67 fluores-
cence and killed/lysed target cells were measured as PKH 67- and
PI-positive cells.
Statistical Analysis
All statistical analyses were performed using Prism GraphPad
Software (San Diego, CA). Wilcoxon’s t-test was used for statistical
analyses. In general, means were used and statistical deviations are
presented as standard deviation unless otherwise noted. A p-
value,0.05 was deemed statistically significant.
Results
Construction and Characterization of a Recombinant
MVA Expressing the HERV-K Envelope Glycoprotein
Like all retroviral envelope proteins, the HERV-K ENV is
translated as a precursor protein from a singly spliced transcript.
The precursor, with a molecular mass of 90 kDa, is processed into
a transmembrane (TM) subunit of 40 kDa with a cytoplasmic and
extracellular domain, and a non-covalently linked surface subunit
that putatively binds the cellular receptor [30]. The entire open
reading frame, which also includes the first exon of the
nucleocytoplasmic shuttle protein Rec, was inserted into the
MVA genome by homologous recombination using the region
flanking deletion VI in the MVA genome. HERV-K ENV gene
expression is thereby under the control of the early/late p7.5
promoter [31]. The recombinant MVA (MVA-HKenv) was
isolated by K1L selection as described before [29], and HERV-
K ENV expression of the final working stock was verified by
Western blot analysis of 293 T cells infected at an MOI of 5
(Fig. 1). ENV expression started at 4 h post infection and the
protein is partially cleaved, because the precursor as well as the
TM subunits were detectable (Fig. 1, indicated by arrows). Two
vaccinations on days 0 and 21 of BALB/c mice with 10
7 IU
MVA-HKenv resulted in the weak generation of ENV-specific
antibodies by the mice, as analyzed on day 47 by immunofluo-
rescence studies with GH cells, which express high levels of
HERV-K ENV protein and are a very sensitive method to detect
HERV-K specific antibodies (data not shown) [32]. In addition,
nucleolar staining was detectable with one mouse serum,
demonstrating an immune response against the co-expressed
Rec protein, which is located in nucleoli (data not shown) [33].
MVA-HKenv Induces Cellular Immune Responses
Retroviral envelope proteins have been described to have
immunosuppressive properties, which have been attributed to
interference with natural killer cell and/or CD8+ T cell effector
functions [34], [35], [36]. Accordingly, we performed a sequence
alignment of the immunosuppressive syncytin-1 sequence (ISD)
with HERV-K ENV; however, we could not identify motifs in
HERV-K ENV homologous to an ISD sequence. Nevertheless, we
examined whether HERV-K ENV expression by MVA interferes
with the induction of cell-mediated immune responses directed
against MVA. C57BL/6 mice were i.v. infected twice with
1610
6 IU MVA or MVA-HKenv, and the induction of MVA-
specific CD8+ T cells was monitored by FACS analysis using a
TSYKFESV-K
b pentamer specific for the immunodominant
vaccinia virus B8R-derived T cell epitope. C57BL/6 mice were
used, because the vaccinia virus specific pentamer is only
commercially available for these mice. B8R-specific CD8+ T cells
expanded with similar kinetics after MVA or MVA-HKenv
immunization (Fig. 2). The boost immunization on day 42 resulted
in a rapid expansion of B8R-specific CD8+ T cells in both groups
(Fig. 2, days 45, 47 and 49). The slightly lower values in MVA-
HKenv immunized mice were not statistically significant (Fig. 2).
Therefore, HERV-K envelope protein expression did not interfere
with the development of an adaptive cell-mediated immune
response against vaccinia virus and implies that HERV-K-directed
CD8+ cells are also likely to be induced.
Establishment of an Animal Model
A major bottleneck in HERV-K-specific vaccine development is
an appropriate animal model, since HERV-K is exclusively
expressed in humans. We therefore adapted a syngeneic mouse
model for this purpose. Murine renal carcinoma cells (Renca) were
genetically altered to express E. coli beta-galactosidase (RLZ cells)
[37] and the HERV-K ENV gene was then introduced by
retroviral transduction (RLZ-HKenv cells). The engineered cell
line RLZ-HKenv is positive for ENV expression at various
intensities as shown by immunofluorescence analysis and showed a
Figure 1. Western Blot analysis of MVA-HKenv-infected 293 T
cells. 293 T cells were infected at an MOI of 5 with MVA-HKenv and cell
lysates were prepared at the indicated time points. HERV-K ENV was
identified with the HERV-K ENV monoclonal antibody HERM-1855
followed by chemiluminescent detection. Arrows indicate the position
of HERV-K ENV subunits. Detection of ß-actin was used as loading
control.
doi:10.1371/journal.pone.0072756.g001
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the secretory pathway (Fig. 3A). The cells can be passaged without
silencing of ENV expression in vitro and in vivo (data not shown).
The growth rate of both cell lines (RLZ and RLZ-HKenv) in tissue
culture was comparable and they both expressed MHC class I at
similar levels (Fig. 3B and C). Intravenous application of RLZ-
HKenv cells into syngeneic BALB/c mice resulted in the
formation of pulmonary metastases, which were detectable by
X-gal staining upon excision of the lungs.
Therapeutic Vaccination with MVA-HKenv Reduces the
Number of Lung Metastases
In a therapeutic setting, the vaccination would be used for the
treatment of established tumors. Therefore, 10
5 RLZ-HKenv cells
were applied intravenously into BALB/c mice on day 0. Ten days
later, after the cells had had the chance to colonize the lung, the
mice were vaccinated intramuscularly with either MVA-HKenv or
MVA (10
7 IU/mouse or 10
8 IU/mouse, respectively; n=7)
(Fig. 4A). On day 45, the mice were sacrificed and the lungs
were excised, fixed and stained for beta-galactosidase. Only a few
pulmonary tumors were detectable in the lungs of MVA-HKenv-
vaccinated animals (Fig. 4B). However, MVA-vaccinated animals
had a much higher tumor burden. Figure 4C summarizes the
number of pulmonary tumors and shows that there was a
statistically significant difference in the number of metastases with
a p-value of 0.019. A single vaccination with MVA-HKenv
dramatically decreased the outgrowth of pulmonary tumors. Still,
the number of metastasis showed high variations and therefore we
repeated the experiment and observed a similar significant
difference. In this experiment, mice treated twice with MVA-
HKenv and showed less metastasis compared to MVA treated
animals. High numbers of metastasis were only observed in mice
treated with MVA.
Prophylactic Vaccination with MVA-HKenv Prevents the
Establishment of HERV-K-Expressing Tumor Metastasis
Cancer vaccination might also be envisioned as a prophylactic
treatment of healthy persons with an elevated genetic risk of
cancer development. To test the prophylactic properties of MVA-
HKenv, BALB/c mice (n=7) were injected intramuscularly on
day 0 with 10
7 IU MVA-HKenv or 10
8 IU MVA and boosted
with the same dose on day 21. On day 33, the mice were injected
i.v. with 5610
5 RLZ-HKenv cells and finally sacrificed on day 69.
One mouse died on day 68 in the MVA-vaccinated group.
Figure 5A summarizes the vaccination schema. Vaccination with
MVA-HKenv completely prevented the formation of RLZ-
HKenv lung metastasis, whereas MVA-vaccinated animals had a
high tumor burden in their lungs (Fig. 5B). The difference between
MVA and MVA-HKenv vaccination was statistically significant
with a p-value of 0.015 (Fig. 5C) and clearly shows the capability
of the vaccination to prevent the establishment of lung metastasis
in this aggressive mouse model. Similar results were obtained in a
second experiment with a challenge dose of 1610
6 RLZ-HKenv
cells. Again the MVA-HKenv-vaccinated group did not support
the colonization of RLZ-HKenv cells, whereas the MVA-
vaccinated group had an average of 21 lung surface metastases.
MVA-HKenv Vaccination Induces Cytotoxic Lymphocytes
able to Kill RLZ-HKenv Cells
To shed light on the underlying mechanism of tumor rejection,
cellular immune responses were analyzed with splenocytes of
Figure 2. Analysis of B8R-specific CD8+ cells. C57BL/6 mice (n=5) were injected i.v. with 10
6 IU MVA or MVA-HKenv. Induction of CD8+ T cells
directed against the vaccinia virus B8R gene product was measured at the indicated time points in blood samples by flow cytometry using an MHC
class I pentamer. Mice were vaccinated on day 0 and arrows indicate the time point of the second virus application on day 42. The p-values between
the two immunization groups were: day 5 p=0.159; day 47 p=0.058; day 49 p=0.472, indicating no significant difference.
doi:10.1371/journal.pone.0072756.g002
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cytolytic effector cells were restimulated by co-cultivation of spleen
cells isolated on day 69 from prophylactically vaccinated animals
with c-irradiated RLZ-HKenv cells and proinflammatory cyto-
kines for 4 days. The restimulated effector cells were harvested on
day 4. After removal of dead cells, they were cocultured at an
effector to target ratio of 5:1 with PKH 67-labeled RLZ-HKenv or
RLZ cells for 6 h. The number of dead target cells was determined
by flow cytometry as the number of propidium iodide (PI) - and
PKH 67-stained double positive cells. Vaccination with MVA-
HKenv induced a higher specific cell killing of RLZ-HKenv cells
compared to RLZ cells (Fig. 6). In contrast, MVA-vaccinated
animals mounted similar cell mediated cytotoxic activities but
towards both cell lines, RLZ and RLZ-HKenv, and no difference
in killing activity between RLZ-HKenv and RLZ cells could be
observed (Fig. 6). Since these mice had a constant exposure to
RLZ cells due to the high tumor burden during the experiment
and at the time point of lymphocyte isolation, it is likely that tumor
growth generated an unspecific immune response towards RLZ
cells, which, however, was not early or strong enough to control
tumor cell growth. However, exposure of the mice to a specific
vaccine prevented tumor outgrowth and induced specific cell-
mediated cytotoxic effector functions against HERV-K ENV-
expressing tumor cells.
Discussion
Cancer immunotherapy relies on the tight association of the
expression of the target gene in the diseased tissue with its lack in
healthy somatic cells. The envelope protein of the human
endogenous retrovirus K fulfills this criterion perfectly. Support
comes from recently published studies which describe that HERV-
K ENV expression is virtually absent in healthy human tissue [24],
[20], however care should be taken to exclude persons with other
HERV-K expression associated diseases as for instance auto
immune diseases [38]. Although another publication described
HERV-K ENV expression in human placenta [25], the above
authors could not confirm these data [24]. Yet, HERV-K ENV
expression is connected with disease and has been observed in
Figure 3. Characterization of RLZ-HKenv cells. A: Immunofluorescence analysis of RLZ cellsCells were fixed and stained either with an anti-
HERV-K ENV antibody alone or in combination with DAPI. B: Growth rate of RLZ cells RLZ and RLZ-HKenv cells were counted for 10 days and the
number of cells was blotted against the time and gives the growth rate of the cell lines. C: MHC class I expression. MHC class I (H2Kd) expression was
analyzed by flow cytometry either with an antibody directed against H2Kd or a control antibody of the same isotype. Human 293 T cells were used as
negative control.
doi:10.1371/journal.pone.0072756.g003
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patients. However, the exact mechanism of HERV-K reactivation
and its functional consequences are still unknown. Currently,
HERV-K reactivation is assumed to be a result of deregulated
epigenetic silencing mechanisms which still need to be studied in
more detail.
Besides tumor-specific protein expression, immune responses to
HERV-K have been found in tumor patients. For instance, anti-
HERV-K antibodies and T cell responses have been detected in
patients with breast and ovarian cancer but not in healthy female
controls [8], [10]. HERV-K seropositivity is both a diagnostic and
prognostic marker for germ cell tumors (GCTs). There is a strong
association of HERV-K antibodies with the clinical manifestation
of the disease as well as therapy failure, and significant
seronegativity for healthy donors [39]. The negative correlation
indicates that HERV-K-directed immune responses have to be
elicited early during tumor formation and with high potency to be
able to compete with tumor growth. Analyzing HERV-K
seropositivity in melanoma patients has revealed an epitope
suitable as a melanoma marker [40]. In addition, a humoral
immune response against HERV-K gene products significantly
correlated with a reduced survival probability of melanoma
patients [7].
Another pathological state associated with HERV-K expression
is HIV-1 infection, where multiple reports suggest that endogenous
retroviruses might be a useful and invariable target for immuno-
therapy [41]. In this case, cell-mediated immune responses
directed against HERV-K correlated with control of HIV-1
viremia [21], [22].
At least 91 full-length HERV-K elements have been reported to
exist in the human genome [1] however they accumulated
mutations to render them non-infectious. In addition about 2500
HERV-K solitary LTRs exist in the human genome, indicating
that they originated from recombinations of full-length HERV-K
genomes. This complex nature of HERV-K should be considered
for vaccine development and might indicate that for tumor
vaccination the here described vaccine based on HERV-K 108 is
the best choice. Recently, the activation of a novel HERV-K
provirus, K111, was found to be activated by HIV infection and
might require using the K111 ENV for vaccine purposes targeting
HIV-infected cells [42].
Here, we generated a HERV-K ENV-directed vector vaccine
based on the modified vaccinia virus Ankara (MVA), a highly
attenuated vaccinia virus strain suitable for clinical application.
MVA does not replicate in human cells but shows high protein
expression and, consequently, has a very good safety profile
without compromising vaccination efficiency. Due to the attenu-
ation, MVA can be used for vaccinations of immunosuppressed
patients [43], [44]. Vaccine efficacy testing of the recombinant
MVA-HKenv was performed in a surrogate mouse model, using a
syngeneic mouse tumor cell line which was genetically engineered
to express HERV-K ENV at different protein levels. Although this
model is quite artificial, it may well reflect the situation in humans.
Since HERV-K expression is normally repressed, it is expected
Figure 4. Specificity of the therapeutic vaccination. A: Schematic diagram of the therapeutic vaccination Two groups of BALB/c mice (n=7)
were injected i.v. with 10
5 RLZ-HKenv cells and immunized with either 10
7 IU/mouse MVA-HKenv or 10
8 IU/mouse MVA i.m. on day 10. The animals
were sacrificed on day 45, lungs were removed, and stained with X-Gal. B: Lungs of mice. The lungs of the animals were excised and stained with X-
gal. Tumor nodules are visible by blue staining of the cells. C: Analysis of tumor nodulesThe number of tumor nodules was counted on the surface of
the lungs. Data for each mouse are shown. The p-value of 0.019 shows significance.
doi:10.1371/journal.pone.0072756.g004
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immune responses are readily seen in cancer and HIV-infected
patients. Formation of pulmonary metastasis in the mice was used
as a measure for vaccine efficiency. In a therapeutic setting, after
the colonization of RLZ-HKenv cells, a single vaccination of the
animals with MVA-HKenv significantly diminished the number of
metastases compared to MVA-vaccinated animals. In addition, the
prophylactic vaccination, this time with two vaccine applications,
completely abolished the formation of lung metastases in the
MVA-HKenv-vaccinated group, whereas the MVA-treated group
succumbed to tumors. The MVA-HKenv-treated animals devel-
oped cell-mediated cytolytic activity against RLZ-HKenv cells,
which is most likely responsible for tumor rejection. The
experimental vaccine MVA-HKenv may therefore represent a
novel treatment for HERV-K-positive tumors or even the HIV-1
infection.
The challenging next step is now to transfer this vaccination
strategy to a clinical situation. Side effects of an HERV-K-specific
vaccination can only be studied in humans. Primates encode very
similar endogenous retroviral genomes and could be used as a
model for safety studies [45], [46], [47], [24]. We showed proof of
principle for an HERV-K cancer vaccine in a mouse tumor
model. In addition, this treatment might also be applicable as an
anti-HIV vaccine, the development of which is still hampered by
the rapid escape of HIV from antiviral host responses. HERV-K
ENV would be available as a constant target for HIV vaccine
development, and can expected to be effective, since HERV-K-
Figure 5. Specificity of the prophylactic vaccination. A: Schematic diagram of the prophylactic vaccination. Two groups of BALB/c mice (n=7)
were immunized i.m. with either 10
7 IU/mouse MVA-HKenv or 10
8 IU/mouse MVA on day 0 and day 21. The mice were injected i.v. with 5610
5 RLZ-
HKenv cells on day 33 and sacrificed on day 69. The lungs were removed and stained with X-Gal. B: Lungs of miceThe lungs of the animals were
excised and stained with X-gal. Tumor nodules are visible by blue staining of the cells. C: Analysis of tumor nodules. The number of lung tumor
nodules was counted on the surface of the lungs and data for each mouse are shown. The p-value of 0.015 shows significance.
doi:10.1371/journal.pone.0072756.g005
Figure 6. Induction of HERV-K ENV-specific cytotoxic activity in
immunized mice. Spleen cells were isolated at the end of the
experiment described in Figure 4. Cells were restimulated and their
specific cytolytic activity against RLZ-HKenv cells was measured by flow
cytometry. RLZ-HKenv and RLZ cells were stained with the cell
membrane-labeling dye PKH 67 and restimulated spleen cells were
cocultivated with labeled RLZ-HKenv/RLZ target cells at a 5:1 ratio for
6 h. Subsequently cells were stained with propidium iodide (PI) and
directly analyzed by flow cytometry. Dead RLZ-HKenv cells are PKH 67-
and PI-positive and the mean values with standard deviations for each
group are indicated. MVA-vaccinated group p=0.34; MVA-HKenv-
vaccinated group p=0.008.
doi:10.1371/journal.pone.0072756.g006
HERV-K Env Tumor Vaccination
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with mild disease progression in AIDS patients [21].
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